Solid Biosciences Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
SLDB$7.17+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $80,235 | $74,015 |
| Available-for-sale securities | 68,685 | 49,625 |
| Prepaid expenses and other current assets | 8,382 | 6,094 |
| Total current assets | 157,302 | 129,734 |
| Non-current assets: | ||
| Operating lease, right-of-use asset | 24,295 | 26,539 |
| Property and equipment, net | 4,747 | 6,624 |
| Other non-current assets | 366 | 209 |
| Restricted cash | 1,952 | 1,833 |
| Total non-current assets | 31,360 | 35,205 |
| Total assets | $188,662 | $164,939 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,237 | $2,032 |
| Accrued expenses and other current liabilities | 19,852 | 10,161 |
| Operating lease liabilities | 1,787 | 1,855 |
| Finance lease liabilities | 1,231 | 469 |
| Derivative liabilities | 3,150 | — |
| Total current liabilities | 30,257 | 14,517 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 21,159 | 22,707 |
| Finance lease obligations, net of current portion | — | 1,234 |
| Total non-current liabilities | 21,159 | 23,941 |
| Total liabilities | 51,416 | 38,458 |
| Commitments and Contingencies (Note 11) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; 120,000,000 and 60,000,000 shares authorized at December 31, 2024 and 2023, respectively; 40,468,141 and 20,386,606 shares issued and outstanding at December 31, 2024 and 2023, respectively | 40 | 20 |
| Additional paid-in capital | 920,609 | 785,199 |
| Accumulated other comprehensive income | 47 | 15 |
| Accumulated deficit | (783,450) | (658,753) |
| Total stockholders' equity | 137,246 | 126,481 |
| Total liabilities and stockholders' equity | $188,662 | $164,939 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.